The P-I clinical trial evaluates GTX-102 in a crossover analysis that assesses the bioavailability, PK & safety of GTX-102 oral spray (0.0125/0.05/0.1 mg/kg) vs betamethasone IM (0.1 mg/kg) & OS (0.1 mg/kg) in healthy individuals (n=48)
The PK outcomes depicted good linearity & dose-proportionality for betamethasone blood concentrations at all dose levels of GTX-102 whereas following a high dose of GTX-102 the concentration was within the same range of exposure as betamethasone IM & OS
Additionally, no difference was seen between the fast rate administration of GTX-102 vs slow rate whereas the Cmax of GTX-102 was within the same range of exposure as OS but was lower for IM
Ref: Globenewswire | Image: Acasti
Related News:- Ultragenyx Enters into a Partnership and Option to Acquire Agreement with GeneTx to Develop its GTX-102 for Angelman Syndrome
